New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim

A new research team at XSeed Labs, a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and fibrosis. The research team has commenced its activities at the Boehringer Ingelheim campus in Ridgefield, Connecticut.

Led by Dr. Lorenzo Talà, the team aims to create physiologically relevant disease models to better understand fibrotic diseases. They will use both in vitro and in silico approaches to investigate disease mechanisms, drug delivery pathways, and drug safety, ultimately facilitating drug development.

Christian Tidona, Founder and Managing Director of the BioMed X Institute, expressed satisfaction in extending their collaboration with Boehringer Ingelheim to the U.S. Carine Boustany and Xiaorong He from Boehringer Ingelheim highlighted the importance of this partnership in accelerating innovation and improving drug delivery strategies.

Mark Johnston, CEO of BioMed X USA, emphasized the unique innovation model of XSeed Labs, promoting scientific exchange in biomedical research.